In this video, Terri E. Weaver, PhD, RN, talks about the next steps in the research of solriamfetol.
Additional Resource:
- Weaver T, Pepin JL, Schwab R, et al. Long-term effects of solriamfetol on excessive daytime sleepiness and functional outcomes in participants with OSA. Paper presented at: CHEST 2020; October 18-21, 2020; Virtual. https://journal.chestnet.org/article/S0012-3692(20)34156-8/fulltext
Terri E. Weaver, PhD, RN, is dean and professor in the Department of Behavioral Nursing Science in the College of Nursing and professor in the Division of Pulmonary, Critical Care, Sleep, and Allergy in the Department of Medicine in the College of Medicine at the University of Illinois at Chicago.
TRANSCRIPT:
My name is Terri Weaver, I am Dean and professor at the University of Illinois Chicago College of Nursing.
I think that we've shown this drug has short- and long-term efficacy and effectiveness. I think, personally in my mind, it is to then look at some of the studies, including our own, that have shown that there is white matter compromise, and there is a problem with myelin diffusivity, and also the axons are damaged.
The relationship between that impact and how this pharmaceutical works. So, is it that it just boosts other mechanisms that compensate for that? Or is it some other means by which it improves alertness in these individuals?
We know that those improve the, as I said, uptake of dopamine and norepinephrine. It does affect the uptake of dopamine and norepinephrine. So, it affects that transmission. But how that relates to what we're seeing on diffusion tensor imaging and other assessments, we're not sure.
We have to take these 2 pieces of what we know is going on from a pathophysiological standpoint, when the action of the drug, and see is there any connection or is it just that it boosts other systems to compensate?
Thank you for the opportunity to share our work, greatly appreciate it.
